EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share (FOCL)

Focal One sales grew, but deal timing pushed some placements into Q4.

FocalTherics (NASDAQ:FOCL) reported 26% growth in third-quarter 2026 revenue from its high-intensity focused ultrasound business, but lowered the top end of its full-year forecast after three anticipated system sales slipped into the fourth quarter. Revenue was $9.8 million, up from $7.8 million a

45% Revenue Increase and 44% Growth in U.S. Procedure Volume Year-to-date

FocalTherics™ to Participate in Upcoming Investor Conferences

Company to host conference call and webcast on Thursday, November 5 at 4:30 p.m. ET

Insiders at H.B. Fuller, FocalTherics, and Cardinal Infrastructure Group are buying shares, signaling potential bottoms backed by analyst price targets, institutional ownership, and growth catalysts.

Company to Present and Host 1x1 Investor Meetings on Tuesday and Wednesday, September 15th-16th, 2026

HIFU revenue surged 39% as system sales jumped 44%, signaling strong adoption momentum.

FocalTherics (NASDAQ:FOCL) reported second-quarter HIFU revenue of $13.2 million, up 39% from $9.5 million a year earlier, as the company continued to expand sales of its Focal One high-intensity focused ultrasound platform for focal therapy. Chief Executive Officer Ryan Rhodes characterized the pe

Edap TMS (NASDAQ:FOCL) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For

39% Revenue Increase and 47% Growth in U.S. Procedures

FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares

FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026

FocalTherics™ Announces Proposed Public Offering of American Depositary Shares

Company to host conference call and webcast on Thursday, August 13 at 4:30 p.m. EDT

FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients

FocalTherics™ Expands Access to Focal One® Robotic HIFU for Veterans with Prostate Cancer through Agreement with MellingMedical